• Home
  • News

Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $8.15 Million Private Placement Offering of SciSparc Ltd. 

SciSparc logo

Press Release – New York, NY – March 5, 2021 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp. as the exclusive placement agent in a private placement of SciSparc Ltd., (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments.

The offering consisted of an aggregate of 1,152,628 Units that were sold to certain institutional and accredited investors as follows: (a) 916,316 units at an offering price of $7.07 per unit, consisting of 1 American Depositary Share (“ADS”), a Series A Warrant to purchase an equal number of Units purchased and a Series B Warrant to purchase half the number of Units and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of 1 pre-funded warrant to purchase one ADS, a Series A Warrant to purchase an equal number of Units purchased and a Series B Warrant to purchase half the number of Units. The Series A Warrants have an exercise price of $7.07, and the Series B Warrants have an exercise price equal to $10.60. The Pre-Funded Warrants have an exercise price of $0.001 per full ADS.  The gross proceeds from the offering were approximately $8.15 million. 

The Sichenzia Ross Ference LLP team was led by partners Darrin M. Ocasio and Avital Perlman, and associate Matthew Siracusa.

Sichenzia Ross Ference LLP
Latest posts by Sichenzia Ross Ference LLP (see all)